Illumina (NASDAQ:ILMN) – Equities research analysts at William Blair raised their Q2 2018 earnings per share estimates for shares of Illumina in a research report issued on Tuesday, May 22nd. William Blair analyst A. Murphy now anticipates that the life sciences company will earn $1.09 per share for the quarter, up from their previous estimate of $1.06. William Blair also issued estimates for Illumina’s Q3 2018 earnings at $1.11 EPS and FY2020 earnings at $6.02 EPS.
Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, April 24th. The life sciences company reported $1.45 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.43. The firm had revenue of $782.00 million during the quarter, compared to analyst estimates of $744.30 million. Illumina had a net margin of 19.31% and a return on equity of 24.93%. The company’s quarterly revenue was up 30.8% on a year-over-year basis. During the same quarter last year, the business earned $0.64 earnings per share.
A number of other equities analysts have also weighed in on ILMN. BTIG Research reiterated a “hold” rating on shares of Illumina in a research report on Wednesday, April 25th. Robert W. Baird increased their price target on shares of Illumina from $261.00 to $271.00 and gave the stock an “outperform” rating in a report on Wednesday, April 25th. ValuEngine raised shares of Illumina from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Canaccord Genuity reissued a “buy” rating and issued a $265.00 price target (up from $255.00) on shares of Illumina in a report on Wednesday, January 31st. Finally, BidaskClub downgraded shares of Illumina from a “buy” rating to a “hold” rating in a report on Saturday, February 3rd. One analyst has rated the stock with a sell rating, five have given a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $251.14.
Shares of Illumina opened at $270.83 on Thursday, MarketBeat reports. The company has a debt-to-equity ratio of 0.23, a current ratio of 2.71 and a quick ratio of 2.41. The stock has a market cap of $39.81 billion, a price-to-earnings ratio of 67.71, a price-to-earnings-growth ratio of 2.78 and a beta of 0.86. Illumina has a twelve month low of $167.98 and a twelve month high of $273.93.
A number of institutional investors and hedge funds have recently made changes to their positions in ILMN. Financial Gravity Companies Inc. purchased a new stake in Illumina in the fourth quarter valued at approximately $106,000. Harvest Fund Management Co. Ltd purchased a new stake in Illumina in the first quarter valued at approximately $113,000. SeaCrest Wealth Management LLC purchased a new stake in Illumina in the fourth quarter valued at approximately $154,000. Captrust Financial Advisors purchased a new position in shares of Illumina during the fourth quarter worth approximately $165,000. Finally, Mitsubishi UFJ Securities Holdings Co. Ltd. raised its stake in shares of Illumina by 113.9% during the fourth quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 770 shares of the life sciences company’s stock worth $168,000 after acquiring an additional 410 shares in the last quarter. 90.75% of the stock is currently owned by institutional investors and hedge funds.
In related news, Director Robert S. Epstein sold 250 shares of the firm’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $231.25, for a total value of $57,812.50. Following the sale, the director now directly owns 7,088 shares of the company’s stock, valued at $1,639,100. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Charles Dadswell sold 145 shares of the firm’s stock in a transaction that occurred on Monday, March 5th. The shares were sold at an average price of $227.17, for a total transaction of $32,939.65. Following the completion of the sale, the senior vice president now directly owns 7,991 shares in the company, valued at $1,815,315.47. The disclosure for this sale can be found here. Insiders sold 27,614 shares of company stock worth $6,965,324 over the last ninety days. 0.54% of the stock is currently owned by insiders.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.